Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 52%
Buy 35%
Hold 9%
Sell 4%
Strong Sell 0%

Bulls say

DexCom is a leader in the continuous glucose monitoring (CGM) industry, and its recent clinical trial results and data support its expanding presence in the diabetic market, including in the large Type 2 non-insulin population. With high adherence rates and positive outcomes across various treatment regimens, DexCom's CGMs offer a complementary tool for Type 2 patients, positioning the company well as CMS expands coverage for this population. Along with solid financial metrics and a strong pipeline of innovation, DexCom presents a sustainable mid-teens revenue growth story with the potential for significant upside in the years to come.

Bears say

DexCom is facing strong competition in the T2NIT market and may not be able to maintain its share against companies such as Abbott Laboratories. Additionally, the lack of traditional financial metrics makes it difficult to determine a price target for the stock. The recent preliminary WW revenue of $1.260B and EPS of $0.68 may suggest a strong financial performance, but GM of 63.5% and a lower tax rate may mask potential weaknesses. The company is also heavily reliant on potential changes in the coverage landscape and may face setbacks in its efforts to secure Medicare coverage, despite optimistic commentary from management.

DexCom (DXCM) has been analyzed by 23 analysts, with a consensus rating of Buy. 52% of analysts recommend a Strong Buy, 35% recommend Buy, 9% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 23 analysts, DexCom (DXCM) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $85.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $85.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.